Alkermes (FRA:8AK) FFO


FRA:8AK Alkermes PLC FRA:8AK
71 GF Score
Price €47.34
GF Value €27.34
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes FFO?

FFO (Funds from operations) only applies to REITs.

FRA:8AK
71GF Score
Alkermes PLC FRA:8AK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alkermes (FRA:8AK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of €47.34 is trading 73.2% above its estimated GF Value™ of €27.34. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for FRA:8AK:

  • FFO:
  • GF Value™: €27.34 vs. price of €47.34 (73.2% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the FRA:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkermes Business Description

Other Exchanges ALKS:USA
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
71GF Score

Get the complete analysis for FRA:8AK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.34
Price
€27.34
GF Value